BML (4694) Q3 2025 earnings summary

Executive summary

• Net sales for the first nine months of FY2025 rose 5.4% year-over-year to ¥114,475 million, driven by new customer acquisition and price optimization.

• Operating profit increased 13.0% year-over-year to ¥9,200 million, and profit attributable to owners of parent rose 24.6% to ¥6,557 million.

• The business environment remained challenging due to rising costs and competition, but no reduction in medical service fees occurred this year.

Financial highlights

• Gross profit for the nine months ended December 31, 2025, was ¥37,886 million, up from ¥35,719 million year-over-year.

• Ordinary profit reached ¥9,628 million, a 14.0% increase year-over-year.

• Basic earnings per share for the period were ¥171.47, up from ¥134.91 in the prior year.

• Comprehensive income rose to ¥6,823 million, a 25.8% increase year-over-year.

Outlook and guidance

• Full-year net sales forecast revised upward to ¥149,000 million, a 4.1% year-over-year increase.

• Operating profit forecast raised to ¥10,000 million (6.8% increase), and profit attributable to owners of parent to ¥7,000 million (11.8% increase).

• Basic earnings per share for the full year projected at ¥183.88.

• Upward revision attributed to steady customer acquisition and successful price optimization.